Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam J Adler

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|September 24, 2002
Effector CD4 cells are tolerized upon exposure to parenchymal self-antigenAmy D Higgins, Marianne A Mihalyo, Adam J Adler
Journal of Visualized Experiments : Jove|December 5, 2013
Infinium assay for large-scale SNP genotyping applicationsAdam J Adler, Graham B Wiley, Patrick M Gaffney
Scientific Reports|July 28, 2019
A mathematical model of combined CD8 T cell costimulation by 4-1BB (CD137) and OX40 (CD134) receptorsAnna Konstorum, Anthony T Vella, Adam J Adler, et al.
Cellular Immunology|November 12, 2003
Effector CD4 cell tolerization is mediated through functional inactivation and involves preferential impairment of TNF-alpha and IFN-gamma expression potentialsMeixiao Long, Amy D Higgins, Marianne A Mihalyo, et al.
Journal of the Royal Society, Interface|June 30, 2017
Addressing current challenges in cancer immunotherapy with mathematical and computational modellingAnna Konstorum, Anthony T Vella, Adam J Adler, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 23, 2002
CD4 cell priming and tolerization are differentially programmed by APCs upon initial engagementAmy D Higgins, Marianne A Mihalyo, Patrick W McGary, et al.
Expert Opinion on Biological Therapy|February 9, 2016
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?Joseph M Ryan, Jeffrey S Wasser, Adam J Adler, et al.
Plos One|February 2, 2023
High glucose promotes regulatory T cell differentiationElise Pitmon, Eileen Victoria Meehan, Elham Ahmadi, et al.
Journal of Leukocyte Biology|October 17, 2008
The IKK-neutralizing compound Bay11 kills supereffector CD8 T cells by altering caspase-dependent activation-induced cell deathSeung-Joo Lee, Meixiao Long, Adam J Adler, et al.
The Prostate|January 16, 2007
Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesisMarianne A Mihalyo, Adam T Hagymasi, Aaron M Slaiby, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Journal of Immunology (Baltimore, Md. : 1950)|September 24, 2002
Effector CD4 cells are tolerized upon exposure to parenchymal self-antigenAmy D Higgins, Marianne A Mihalyo, Adam J Adler
Journal of Visualized Experiments : Jove|December 5, 2013
Infinium assay for large-scale SNP genotyping applicationsAdam J Adler, Graham B Wiley, Patrick M Gaffney
Scientific Reports|July 28, 2019
A mathematical model of combined CD8 T cell costimulation by 4-1BB (CD137) and OX40 (CD134) receptorsAnna Konstorum, Anthony T Vella, Adam J Adler, et al.
Cellular Immunology|November 12, 2003
Effector CD4 cell tolerization is mediated through functional inactivation and involves preferential impairment of TNF-alpha and IFN-gamma expression potentialsMeixiao Long, Amy D Higgins, Marianne A Mihalyo, et al.
Journal of the Royal Society, Interface|June 30, 2017
Addressing current challenges in cancer immunotherapy with mathematical and computational modellingAnna Konstorum, Anthony T Vella, Adam J Adler, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 23, 2002
CD4 cell priming and tolerization are differentially programmed by APCs upon initial engagementAmy D Higgins, Marianne A Mihalyo, Patrick W McGary, et al.
Expert Opinion on Biological Therapy|February 9, 2016
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?Joseph M Ryan, Jeffrey S Wasser, Adam J Adler, et al.
Plos One|February 2, 2023
High glucose promotes regulatory T cell differentiationElise Pitmon, Eileen Victoria Meehan, Elham Ahmadi, et al.
Journal of Leukocyte Biology|October 17, 2008
The IKK-neutralizing compound Bay11 kills supereffector CD8 T cells by altering caspase-dependent activation-induced cell deathSeung-Joo Lee, Meixiao Long, Adam J Adler, et al.
The Prostate|January 16, 2007
Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesisMarianne A Mihalyo, Adam T Hagymasi, Aaron M Slaiby, et al.
Pageof 6